Department of geriatric Psychiatry, The Third Hospital of Daqing, Daqing, China.
Clinical laboratory, The Third Hospital of Daqing, Daqing, China.
BMC Psychiatry. 2024 Mar 4;24(1):179. doi: 10.1186/s12888-024-05636-z.
People with schizophrenia often face challenges such as lower psychological resilience, reduced self-worth, and increased social stigma, hindering their recovery. Mindfulness-Based Cognitive Therapy (MBCT) has shown promise in boosting psychological resilience and self-esteem while diminishing stigma. However, MBCT demands professional involvement and substantial expenses, adding to the workload of professionals and the financial strain on patients. Mixed-mode Mindfulness-Based Cognitive Therapy (M-MBCT) integrates both "face-to-face" and "self-help" approaches to minimize staff effort and costs. This study aims to assess the impact of M-MBCT on the psychological resilience, self-esteem, and stigma in schizophrenia patients.
This randomized, controlled, parallel-group, assessor-blinded clinical trial enrolled 174 inpatients with schizophrenia. Participants were randomly assigned to either the experimental or control group. The experimental group underwent an 8-week M-MBCT intervention, while the control group received standard treatment. Data collection employed the Connor-Davidson Resilience Scale (CD-RISC), Internalized Stigma of Mental Illness Scale (ISMI), and Rosenberg Self-Esteem Scale (RSES) before and after the intervention. Post-intervention, significant differences in ISMI, CD-RISC, and RSES scores were observed between the experimental and control groups.
In the experimental group, ISMI scores notably decreased, while CD-RISC and RSES scores significantly increased (P < 0.05). Multiple linear regression analysis identified age, education, and family history of mental illness as significant factors related to stigma (P < 0.05). Additionally, correlation analysis indicated a significant negative relationship between the reduction in CD-RISC scores and the reduction in ISMI scores (P < 0.05).
M-MBCT effectively enhanced psychological resilience and self-esteem while diminishing stigma in individuals with schizophrenia. M-MBCT emerges as a promising treatment option for schizophrenia sufferers.
The trial was registered at the Chinese Clinical Trial Registry on 03/06/2023 ( www.chictr.org.cn ; ChiCTR ID: ChiCTR2300069071).
精神分裂症患者常常面临心理韧性较低、自我价值感降低和社会污名增加等挑战，这阻碍了他们的康复。基于正念认知疗法（MBCT）已被证明可以提高心理韧性和自尊心，同时减少污名。然而，MBCT 需要专业人员的参与和大量的费用，这增加了专业人员的工作量和患者的经济负担。混合模式基于正念认知疗法（M-MBCT）结合了“面对面”和“自助”方法，以最小化员工的努力和成本。本研究旨在评估 M-MBCT 对精神分裂症患者心理韧性、自尊心和污名的影响。
这是一项随机、对照、平行组、评估者盲法的临床试验，共纳入 174 名精神分裂症住院患者。参与者被随机分配到实验组或对照组。实验组接受 8 周的 M-MBCT 干预，而对照组接受标准治疗。在干预前后使用 Connor-Davidson 韧性量表（CD-RISC）、内化精神疾病污名量表（ISMI）和罗森伯格自尊量表（RSES）进行数据收集。干预后，实验组和对照组的 ISMI、CD-RISC 和 RSES 评分均有显著差异。
在实验组中，ISMI 评分显著下降，而 CD-RISC 和 RSES 评分显著增加（P<0.05）。多线性回归分析确定年龄、教育程度和精神疾病家族史是与污名相关的重要因素（P<0.05）。此外，相关分析表明，CD-RISC 评分的降低与 ISMI 评分的降低呈显著负相关（P<0.05）。
M-MBCT 可有效增强精神分裂症患者的心理韧性和自尊心，同时减轻污名。M-MBCT 是精神分裂症患者的一种有前途的治疗选择。
该试验于 2023 年 3 月 6 日在中国临床试验注册中心注册（www.chictr.org.cn；ChiCTR ID：ChiCTR2300069071）。
